GO
Loading...

Gilead Sciences Inc

More

  • NEW YORK, Dec 23- U.S. stock index futures were little changed on Tuesday, after the Dow and S&P 500 closed at fresh records and ahead of a raft of economic data. *Major Wall Street indexes have risen for four straight sessions, pushing the benchmark S&P index to its 50th record high of the year. The S&P has risen 5.4 percent over that period, its best 4- day run since July...

  • Asian shares up after Dow surpasses 18,000 points Tuesday, 23 Dec 2014 | 4:31 AM ET

    In a year full of market milestones, Wall Street crushed a couple more Tuesday, lifting the Dow Jones industrial average past the 18,000- point mark for the first time and delivering the Standard& Poor's 500 index its second record-high close in two days. Investors welcomed the latest encouraging news on the economy as the government said the U.S. grew at the...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Final Glance: Biotechnology companies Monday, 22 Dec 2014 | 7:19 PM ET

    Amgen Inc. fell $5.64 or 3.3 percent, to $164.53. Biogen Idec fell $8.38 or 2.3 percent, to $352.29. Celgene Corp. fell $3.68 or 3.1 percent, to $113.50.

  • Cramer Remix: This sector is on fire Monday, 22 Dec 2014 | 7:05 PM ET
    Jim Cramer on Mad Money.

    It’s alive! "Mad Money" host Jim Cramer has the way to play an industry that’s buzzing again.

  • Your first trade for Tuesday Monday, 22 Dec 2014 | 6:28 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Cramer: Competition + stocks = Cold-blooded killer Monday, 22 Dec 2014 | 6:11 PM ET
    Facebook headquarters

    Price competition might be a good thing for the consumer, but Jim Cramer recommends running far from the stocks—especially in this sector.

  • Ocwen and Gilead are big market movers Monday, 22 Dec 2014 | 5:30 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Ocwen Financial Corp., down $5.89 to $16.01. Nabors Industries Ltd., down 53 cents to $13.10.

  • NEW YORK, Dec 22- Equity markets worldwide edged higher on Monday after rising expectations for more European stimulus supported shares in the region, while year-end buying underpinned U.S. stocks. Anticipation of outright government bond buying from the European Central Bank and greater political stability in Greece boosted European bourses.

  • Dec 22- The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's treatments after trying for nearly a year to win a deeper discount. Express Scripts' move reignited investor concerns that pharmaceutical companies...

  • Midday Glance: Biotechnology companies Monday, 22 Dec 2014 | 1:22 PM ET

    Amgen Inc. fell $3.99 or 2.3 percent, to $166.18. Biogen Idec fell $4.67 or 1.3 percent, to $356.00. Celgene Corp. fell $2.48 or 2.1 percent, to $114.70.

  • Nasdaq stocks posting largest percentage decreases Monday, 22 Dec 2014 | 1:22 PM ET

    Altisource Portfolio Solutions SA fell 31.3 percent to $32.65. Corium Intl Inc. fell 16.4 percent to $6.56. Rex Energy Corp. fell 13.4 percent to $5.60.

  • Most active Nasdaq-traded stocks Monday, 22 Dec 2014 | 1:22 PM ET

    Achillion Pharmaceuticals Inc. rose 9.0 percent to $15.49 with 34,936,200 shares traded. Apple Inc. rose 1.0 percent to $112.94 with 41,476,900 shares traded. BlackBerry Ltd. rose 6.9 percent to $10.68 with 23,336,800 shares traded.

  • *Company to test combination hep C drug in 2015. Dec 22- Data from Achillion Pharmaceuticals Inc's hepatitis C drug trials showed the company could develop a shorter-duration treatment rivaling offerings from Gilead Sciences Inc and Abbvie Inc.. The biotechnology company's shares rose as much as 17 percent to $16.77, their highest in more than seven years.

  • NEW YORK, Dec 22- Equity markets worldwide edged higher on Monday after European energy shares rose, even as oil prices remained volatile. A rebound in European energy shares and greater political stability in Greece boosted European bourses. Stocks in Moscow also gained, with the dollar-traded up almost 7 percent following news that oil firm Rosneft had paid...

  • Gilead falls as Express Scripts picks AbbVie treatment. Express Scripts, the nation's largest pharmacy benefit manager, said it would no longer cover Gilead's treatments after it lined up a cheaper price from AbbVie Inc for its newly approved hepatitis C treatment. "That is very specific to Gilead, so that one is getting crushed, but it shouldn't necessarily set...

  • Dec 22- The nation's largest pharmacy benefit manager has lined up a cheaper price from AbbVie Inc on its newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc treatments, Express Scripts said on Monday. Express Scripts has opposed the $84,000 pricetag of Gilead Sciences' Sovaldi treatment since it was approved a year...

  • Early Glance: Biotechnology companies Monday, 22 Dec 2014 | 10:22 AM ET

    Amgen Inc. fell $3.09 or 1.8 percent, to $167.08. Biogen Idec fell $8.52 or 2.4 percent, to $352.15. Celgene Corp. fell $2.48 or 2.1 percent, to $114.70.

  • *Gilead falls as Express Scripts picks AbbVie treatment. NEW YORK, Dec 22- U.S. stocks were modestly higher on Monday, after the benchmark S&P 500 notched its best weekly performance in nearly two months, as a sharp drop in Gilead Sciences reined in broader gains. Express Scripts, the nation's largest pharmacy benefit manager, has lined up a cheaper price from AbbVie...

  • NEW YORK, Dec 22- U.S. stocks opened modestly higher on Monday, after the benchmark S&P 500 notched its best weekly performance in nearly two months, but a sharp drop in Gilead Sciences weighed on the market.